Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report.
Interleukin 1 (IL1) plays an important role in adult onset Still's disease. Anakinra (Kineret), a recombinant IL1 Receptor Antagonist (IL 1 RA) was therefore recently proposed in adult onset Still's disease with great efficacy. Anakinra appeared to be well tolerated and safe. The case of a patient with refractory adult onset Still's disease who experienced a Systemic Inflammatory Response Syndrome and Adult Respiratory Distress Syndrome requiring intensive care unit hospitalization 10 days after the introduction of anakinra is reported.
Guignard
S
S
Paris 5 Medicine Faculty, Cochin Hospital, Rheumatology B Department, Paris, France. sandra.guignard@free.fr
Dien
G
G
Dougados
M
M
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000009:adverse effects* / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000502:physiology; D008297:Male; D012128:Respiratory Distress Syndrome / Q000139:chemically induced; D016706:Still's Disease, Adult-Onset / Q000188:drug therapy* / Q000503:physiopathology; D018746:Systemic Inflammatory Response Syndrome / Q000139:chemically induced* / Q000175:diagnosis
D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1